Biotechnology AIM Immunotech FDA Lifts Hold, Stock Surges 25%By MohamedMis2July 29, 2023 In a significant development, the FDA has recently lifted its hold on AIM Immunotech. Resulting in a remarkable 25% surge…
Biotechnology AIM ImmunoTech Ovarian Cancer Trial Giving Positive ResultsBy MohamedMis2July 29, 2023 In a recent phase 1/2 clinical trial, AIM ImmunoTech has announced encouraging results from its study involving ovarian cancer patients.…
Asset Management AIM ImmunoTech reported a GAAP EPS of -$0.40By MohamedMis2July 17, 2023 AIM ImmunoTech recently reported disappointing financial results, with a GAAP EPS of -$0.40 and revenue of $0.14M [1]. This signifies…
